These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21233641)

  • 41. Ischemia/reperfusion-induced increase in the hepatic level of prostacyclin is mainly mediated by activation of capsaicin-sensitive sensory neurons in rats.
    Harada N; Okajima K; Uchiba M; Katsuragi T
    J Lab Clin Med; 2002 Apr; 139(4):218-26. PubMed ID: 12024109
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal effects of cyclooxygyenase-2-selective inhibitors.
    Brater DC
    J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S15-20; discussion S21-3. PubMed ID: 11992745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
    Meyer-Kirchrath J; Schrör K
    Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations.
    FitzGerald GA
    Am J Cardiol; 2002 Mar; 89(6A):26D-32D. PubMed ID: 11909558
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
    Krum H; Liew D; Aw J; Haas S
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):265-70. PubMed ID: 15151474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of nitric oxide synthase and cyclooxygenase inhibition on cutaneous microvascular reactivity.
    Lenasi H; Strucl M
    Eur J Appl Physiol; 2008 Aug; 103(6):719-26. PubMed ID: 18516617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. COX-2 inhibitors and metabolism of essential fatty acids.
    Das UN
    Med Sci Monit; 2005 Jul; 11(7):RA233-7. PubMed ID: 15990700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin.
    Xavier FE; Aras-López R; Arroyo-Villa I; del Campo L; Salaices M; Rossoni LV; Ferrer M; Balfagón G
    Br J Pharmacol; 2008 Jul; 154(6):1225-35. PubMed ID: 18500359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors.
    Gambaro G; Perazella MA
    J Intern Med; 2003 Jun; 253(6):643-52. PubMed ID: 12755960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Renal tolerance of selective inhibitors of cyclooxygenase type 2].
    Deray G
    Presse Med; 2001 Oct; 30(30):1507-12. PubMed ID: 11712212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparative study to evaluate the cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients.
    Bhosale UA; Quraishi N; Yegnanarayan R; Devasthale D
    J Basic Clin Physiol Pharmacol; 2015 Jan; 26(1):73-9. PubMed ID: 24620015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of prostacyclin in the cardiovascular response to thromboxane A2.
    Cheng Y; Austin SC; Rocca B; Koller BH; Coffman TM; Grosser T; Lawson JA; FitzGerald GA
    Science; 2002 Apr; 296(5567):539-41. PubMed ID: 11964481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Nonsteroidal anti-inflammatory drugs and the risk of cardiovascular diseases].
    Jukić A; Kaliterna DM; Radić M
    Reumatizam; 2010; 57(1):26-8. PubMed ID: 20941937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Why do COX-2 inhibitors increase risk of cardiovascular events?
    Frankish H
    Lancet; 2002 Apr; 359(9315):1410. PubMed ID: 11978344
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine.
    Gross GJ; Moore J
    Pharmacology; 2004 Jul; 71(3):135-42. PubMed ID: 15161995
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclooxygenase inhibition prior to ventricular fibrillation induced ischemia reperfusion injury impairs survival and outcomes.
    Adams JA; Uryash A; Lopez JR
    Med Hypotheses; 2020 Feb; 135():109485. PubMed ID: 31734378
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective COX-2 inhibitors and risk of myocardial infarction.
    Krotz F; Schiele TM; Klauss V; Sohn HY
    J Vasc Res; 2005; 42(4):312-24. PubMed ID: 15976506
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases.
    Li H; Hortmann M; Daiber A; Oelze M; Ostad MA; Schwarz PM; Xu H; Xia N; Kleschyov AL; Mang C; Warnholtz A; Münzel T; Förstermann U
    J Pharmacol Exp Ther; 2008 Sep; 326(3):745-53. PubMed ID: 18550689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.